PHXM Stock Overview
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
PHAXIAM Therapeutics S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.10 |
52 Week High | €13.00 |
52 Week Low | €2.50 |
Beta | 1.8 |
1 Month Change | -22.31% |
3 Month Change | -34.32% |
1 Year Change | -57.71% |
3 Year Change | -95.87% |
5 Year Change | -96.34% |
Change since IPO | -98.73% |
Recent News & Updates
Recent updates
ERYTECH receives non-compliance letter from Nasdaq
Oct 13Erytech Pharma reports 1H results
Sep 12Erytech drops plans to pursue FDA approval for leukemia therapy
Aug 24Our First Look At ERYTECH Pharma
Nov 16ERYTECH Pharma S.A. 2021 Q1 - Results - Earnings Call Presentation
May 06ERYTECH starts patient enrollment in pancreatic cancer study
Jan 14ERYTECH secures €10M in non-dilutive financing
Nov 02ERYTECH: Trials In Pancreatic Cancer
Oct 23Shareholder Returns
PHXM | US Biotechs | US Market | |
---|---|---|---|
7D | 3.0% | 0.9% | 0.4% |
1Y | -57.7% | 10.3% | 28.8% |
Return vs Industry: PHXM underperformed the US Biotechs industry which returned 13.8% over the past year.
Return vs Market: PHXM underperformed the US Market which returned 30.9% over the past year.
Price Volatility
PHXM volatility | |
---|---|
PHXM Average Weekly Movement | 16.1% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PHXM's share price has been volatile over the past 3 months.
Volatility Over Time: PHXM's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 45 | Thibaut Fayet | https://www.phaxiam.com |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
PHAXIAM Therapeutics S.A. Fundamentals Summary
PHXM fundamental statistics | |
---|---|
Market cap | US$18.92m |
Earnings (TTM) | -US$13.06m |
Revenue (TTM) | US$6.23m |
3.0x
P/S Ratio-1.4x
P/E RatioIs PHXM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHXM income statement (TTM) | |
---|---|
Revenue | €5.70m |
Cost of Revenue | €0 |
Gross Profit | €5.70m |
Other Expenses | €17.66m |
Earnings | -€11.96m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 20, 2024
Earnings per share (EPS) | -1.97 |
Gross Margin | 100.00% |
Net Profit Margin | -209.79% |
Debt/Equity Ratio | 41.3% |
How did PHXM perform over the long term?
See historical performance and comparison